Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system... Show more
Foghorn Therapeutics Inc. is a Cambridge, Massachusetts-based clinical-stage biotechnology company that develops a new class of precision medicines targeting the chromatin regulatory system. Using its proprietary Gene Traffic Control platform, the company identifies and drugs genetically determined dependencies that drive cancer and other serious diseases. Foghorn has historically pursued programs such as FHD-286, a BRG1/BRM ATPase inhibitor, and FHD-609, a BRD9 protein degrader, while building a pipeline of selective degraders and small molecules across oncology and immunology. With no approved products, the company's value is tied closely to clinical data readouts, strategic partnerships, and its ability to fund research through partnerships or capital raises. Investors follow the stock for its platform potential, its collaborations with large pharmaceutical companies, and its pipeline of early-stage oncology and immunology programs.
Over the last 30 days, FHTX shares fell from approximately $3.52 to around $2.05, a decline of roughly 41.8%. The drop was sharpest in early October, when a single-session selloff drove the stock from the mid-$3 range toward $2, with unusually heavy trading volume and an intraday low near $1.79. Over the last quarter, the decline has been even more pronounced: shares traded near $5 in late July and briefly touched the $7 range in mid-August before a sustained slide brought the stock to around $2 by late October, a cumulative decline of about 60%. The trend reflects a steady erosion of investor confidence following the loss of the company's lead clinical program and its primary development partnership.
The primary catalyst was Foghorn's October 1, 2026 announcement that, following a review of Phase 1 dose-escalation data, the company and Eli Lilly (LLY) would not advance FHD-909 (LY4050784), a selective SMARCA2 inhibitor, into the expansion phase of its clinical trial. The companies also elected not to advance a separate selective SMARCA2 degrader program and said they did not anticipate further collaboration activities, effectively ending the partnership. Foghorn said the drug achieved a favorable safety profile and hit its target exposures but did not demonstrate sufficient efficacy to justify further development. The company announced a workforce reduction of approximately 40% and a strategic pivot toward wholly owned programs, including a selective EP300 degrader, a selective CBP degrader, a novel oral immunology and inflammation program, and its induced proximity platform. The restructuring is expected to extend the cash runway into the second half of 2029, with $167.6 million in cash reported as of June 30, 2026. In response, Wedbush downgraded the stock to Neutral with a $2 target, Evercore ISI moved to In Line with a $3 target, and Stifel, H.C. Wainwright, and Guggenheim retained Buy ratings while cutting targets to $5.
The quarterly decline reflects a broader loss of conviction in Foghorn's near-term clinical story. Entering the third quarter, the stock had recovered from earlier setbacks and traded above $5, buoyed by the prospect of FHD-909 advancing through its Phase 1 trial under the Lilly collaboration and by progress across the company's degraders. That momentum faded through September as shares drifted lower, and it collapsed in early October when the FHD-909 data failed to support continued development. The end of the Lilly collaboration removed both a validated partner and a key driver of the prior bull thesis, while the accompanying pipeline reprioritization shifted the investment narrative toward earlier-stage, wholly owned programs that remain years from potential clinical proof-of-concept. The workforce reduction and extended runway provided balance-sheet support but did not offset the loss of the lead asset.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the most relevant and best-performing bots appear in this section. These robots vary widely in their strategies, timeframes, and performance metrics, allowing traders to explore approaches that range from short-term momentum plays to longer-horizon trend following. For investors tracking volatile names such as FHTX, reviewing the Trending AI Robots page can offer a data-driven perspective on how automated systems are interpreting current market conditions.
Looking ahead, investors will focus on Foghorn's progress toward advancing its wholly owned pipeline into clinical development, particularly the selective EP300 degrader, for which the company has targeted an Investigational New Drug application in 2027. The novel oral immunology and inflammation program, the selective CBP degrader, and the ARID1B degrader are also potential value drivers as preclinical data mature. Key financial considerations include the company's cash position and runway, its ability to secure new partnerships or financing, and any further restructuring measures. Macroeconomic factors such as interest rates and risk appetite for speculative biotech names, along with sector-wide sentiment toward early-stage drug developers, may also influence trading. As always, clinical data readouts, regulatory milestones, and analyst revisions will be the primary catalysts to monitor.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for FHTX moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 57 cases where FHTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 28 of 35 cases over the following month. The odds of a continued upward trend are 80%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHTX as a result. In 63 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.370) is normal, around the industry mean (3.586). P/E Ratio (-1.889) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FHTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology